Abstract
The epidemic of neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, and cerebral ischemia (e.g., stroke), has long been a worldwide health and social concern with the rapid increase of aging population. To date, efficient therapeutic drugs are still insufficient, making the treatment of these diseases a big challenge to both basic researchers and clinical physicians. A few in vitro and in vivo experimental models are established to explore, as well as evaluate, protective and therapeutic agents. Among these models, cell-based screening models play an important role in the initial step of searching and identifying neuroprotective compounds. Primary cultured hippocampal and cortical neurons, as well as PC12 and SH-SY5Y cells, are among the frequently applied cells in these models. PC12 is an immortalized pheochromocytoma cell line that provides a series of classical screening models by applying a variety of neurotoxins, such as 6-hydroxydopamine, beta amyloid, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and paraquat, among others. In the present review, several neuroprotective and injury models induced by 4-hydroxynonenal, ethanol, high glucose, homocysteine, okadaic acid, rotenone, and oxygen-glucose deprivation, as well as documented protective agents, are discussed.
Keywords: Neuroprotective agent screening model, PC12, Oxidative stress, SCREENING MODELS, hydrogen peroxide, mitochondrial, Rotenone, Okadaic Acid, prostaglandin, antiepileptic, hypoxia-reoxygenation, mebudipine, ginsenoside, hippocampal, neurotoxins
Current Psychopharmacology
Title: Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Volume: 1
Author(s): Xiuping Chen, Jiajie Guo, Jiaolin Bao, Wenshan Xu, Yanjuan Huang and Yitao Wang
Affiliation:
Keywords: Neuroprotective agent screening model, PC12, Oxidative stress, SCREENING MODELS, hydrogen peroxide, mitochondrial, Rotenone, Okadaic Acid, prostaglandin, antiepileptic, hypoxia-reoxygenation, mebudipine, ginsenoside, hippocampal, neurotoxins
Abstract: The epidemic of neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, and cerebral ischemia (e.g., stroke), has long been a worldwide health and social concern with the rapid increase of aging population. To date, efficient therapeutic drugs are still insufficient, making the treatment of these diseases a big challenge to both basic researchers and clinical physicians. A few in vitro and in vivo experimental models are established to explore, as well as evaluate, protective and therapeutic agents. Among these models, cell-based screening models play an important role in the initial step of searching and identifying neuroprotective compounds. Primary cultured hippocampal and cortical neurons, as well as PC12 and SH-SY5Y cells, are among the frequently applied cells in these models. PC12 is an immortalized pheochromocytoma cell line that provides a series of classical screening models by applying a variety of neurotoxins, such as 6-hydroxydopamine, beta amyloid, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and paraquat, among others. In the present review, several neuroprotective and injury models induced by 4-hydroxynonenal, ethanol, high glucose, homocysteine, okadaic acid, rotenone, and oxygen-glucose deprivation, as well as documented protective agents, are discussed.
Export Options
About this article
Cite this article as:
Chen Xiuping, Guo Jiajie, Bao Jiaolin, Xu Wenshan, Huang Yanjuan and Wang Yitao, Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010103
DOI https://dx.doi.org/10.2174/2211556011201010103 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine Recent Advancements in Liposome-Based Strategies for Effective Drug Delivery to the Brain
Current Medicinal Chemistry Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors
Letters in Drug Design & Discovery Snake Venom L-Amino Acid Oxidases: Some Consideration About their Functional Characterization
Protein & Peptide Letters Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Current Medicinal Chemistry Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress
Current Drug Metabolism Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry STAT3 Regulation of Glioblastoma Pathogenesis
Current Molecular Medicine MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Integrin-Mediated Drug Resistance
Current Signal Transduction Therapy